Loading…
Reported covered position: Aug-Dec2013InternHHSOfficeGenCounselPublicHealth
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| AMERICAN GERIATRICS SOCIETY |
| 15 |
| 2017–2020 |
| LIEBER INSTITUTE FOR BRAIN DEVELOPMENT | 14 | 2016–2019 |
| ACERA SURGICAL | 12 | 2019–2022 |
| INFOCARE HEALTH SERVICES (USA) LLC | 12 | 2018–2020 |
| DEXCOM INC | 11 | 2015–2018 |
| 21ST CENTURY ONCOLOGY | 8 | 2016–2018 |
| FERRING PHARMACEUTICALS, INC. | 8 | 2019–2021 |
| PROVENTION BIO, INC. | 8 | 2021–2023 |
| AMERICAN COUNSELING ASSOCIATION | 6 | 2020–2021 |
| CONNECTICUT CHILDREN'S MEDICAL CENTER | 6 | 2019 |
| INFUSYSTEM | 6 | 2015–2016 |
| BROOKDALE SENIOR LIVING INC. | 5 | 2021 |
| BRUIN BIOMETRICS | 5 | 2019–2020 |
| COLORADO REGIONAL HEALTH INFORMATION ORGANIZATION | 5 | 2020–2021 |
| EDGE THERAPEUTICS INC. | 5 | 2017–2018 |
| ENDEAVORS | 5 | 2018–2019 |
| NEBRASKA HEALTH INFORMATION INITIATIVE | 5 | 2020 |
| AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION | 4 | 2018 |
| ORGANOGENESIS | 4 | 2018–2019 |
| PHATHOM PHARMACEUTICALS | 4 | 2021 |
| ALVOGEN | 3 | 2021 |
| CERBERUS CAPITAL MANAGEMENT, LP ON BEHALF OF STEWARD HEALTH CARE | 3 | 2020 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 3 | 2026 |
| SANDATA TECHNOLOGIES LLC | 3 | 2016 |
| STRATUS | 3 | 2019–2020 |
| AGENDIA | 2 | 2017 |
| OPEN PHILANTHROPY ACTION FUND | 2 | 2021 |
| REBIOTIX, INC. | 2 | 2016 |
| SAMSUNG ELECTRONICS CO. LTD. | 1 | 2017 |
| WARBY PARKER | 1 | 2017 |
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing, related to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (H.R. 4368), and the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (S. 2131).
Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing, related to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (H.R. 4368), and the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (S. 2131).
Lower Costs, More Cures Act of 2021
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); and the Build Back Better Act (H.R.5376).
Lower Costs, More Cures Act of 2021
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); Build Back Better Act (H.R. 5376); and the Inflation Reduction Act (H.R. 5376).
Lower Costs, More Cures Act of 2021
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873 & H.R. 1946).
Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873 & H.R. 1946).
Elijah E. Cummings Lower Drug Costs Now Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); Build Back Better Act (H.R. 5376); and the Inflation Reduction Act (H.R. 5376).
Elijah E. Cummings Lower Drug Costs Now Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); and the Build Back Better Act (H.R.5376).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209), the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348), and the Consolidated Appropriations Act, 2023 (P.L. No: 117-328).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295) and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294).
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Fiscal Year 2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Act (H.R. 4502), and the Fiscal Year 2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 8295). Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health and emergency department renovations.
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues.
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues.
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies appropriations issues. Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health and emergency department renovations.
Inflation Reduction Act of 2022
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); and the Build Back Better Act (H.R.5376).
Inflation Reduction Act of 2022
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
Inflation Reduction Act of 2022
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); Build Back Better Act (H.R. 5376); and the Inflation Reduction Act (H.R. 5376).
COVID–19 Access to Testing and Support for Immune Response Research Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to lab analysis, review, coverage, and reimbursement of diagnostics and lab developed tests, including CMS coverage of T-cell immunity tests. This includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
COVID–19 Access to Testing and Support for Immune Response Research Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
COVID–19 Access to Testing and Support for Immune Response Research Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
COVID–19 Access to Testing and Support for Immune Response Research Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to lab analysis, review, coverage, and reimbursement of diagnostics and lab developed tests, including CMS coverage of T-cell immunity tests. This includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295) and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294).
Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295) and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295) and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Fiscal Year 2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Act (H.R. 4502), and the Fiscal Year 2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 8295). Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health and emergency department renovations.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873 & H.R. 1946).
Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873 & H.R. 1946).
Lower Costs, More Cures Act of 2021
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
Lower Costs, More Cures Act of 2021
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); Build Back Better Act (H.R. 5376); and the Inflation Reduction Act (H.R. 5376).
Lower Costs, More Cures Act of 2021
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); and the Build Back Better Act (H.R.5376).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209), the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348), and the Consolidated Appropriations Act, 2023 (P.L. No: 117-328).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209), the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348), and the Consolidated Appropriations Act, 2023 (P.L. No: 117-328).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295) and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295) and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: ADAPTIVE BIOTECHNOLOGIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
American Rescue Plan Act of 2021
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicaid and other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus, including in the American Rescue Plan Act (H.R. 1319).
American Rescue Plan Act of 2021
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, and the American Rescue Plan Act (H.R. 1319). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health.
American Rescue Plan Act of 2021
Client: CHILDRENS HEALTH SYSTEM OF TEXAS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high cost specialty drugs, and other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus, including in the American Rescue Plan Act (H.R. 1319). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136).
American Rescue Plan Act of 2021
Client: CHILDREN'S HOSPITAL OF THE KING'S DAUGHTERS · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicaid and other pediatric health issues; policy issues related to hospitals and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations; and the American Rescue Plan Act (H.R. 1319).
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to various healthcare reform and drug pricing.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to various healthcare reform and drug pricing.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to various healthcare reform and drug pricing.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). Issues related to biopharmaceutical intellectual property and patent matters.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). Issues related to biopharmaceutical intellectual property and patent matters.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · RA
Issues related to access, coverage, and payment for cancer drugs.
Issues related to access, coverage, and payment for cancer drugs.
Issues related to access, coverage, and payment for cancer drugs.
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · 4A
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to R&D tax credits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to R&D tax credits.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing, related to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (H.R. 4368), and the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (S. 2131).
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to R&D tax credits.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing.
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to R&D tax credits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to R&D tax credits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing.
Issues related to Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · fourth_quarter · Q4
Senate and House Appropriations Committees report language on nuclear medicine event reporting.
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · fourth_quarter · Q4
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · fourth_quarter · Q4
Issues related to Medicaid, coordinated care models for children's health, telehealth, the Children's Health Insurance Program (CHIP), medical education, high-cost specialty drugs, pediatric mental health, hospital funding, and other pediatric health issues.
Issues related to Medicaid, CHIP, hospital funding, Texas' Medicaid 1115 Waiver, and other pediatric health issues.
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · fourth_quarter · Q4
Issues related to R&D tax credits.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · fourth_quarter · Q4
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209), the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348), and the Consolidated Appropriations Act, 2023 (P.L. No: 117-328).
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · third_quarter · Q3
Senate and House Appropriations Committees report language on nuclear medicine event reporting.
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · third_quarter · Q3
Issues related to Medicaid, coordinated care models for children's health, telehealth, the Children's Health Insurance Program (CHIP), medical education, high-cost specialty drugs, pediatric mental health, hospital funding, and other pediatric health issues.
Issues related to federal funding for childrens hospitals, including the Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 (H.R. 4502); Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (S. 4659/H.R. 8295); Congressionally Directed Spending requests for projects related to pediatric mental health care and emergency department renovations.
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · third_quarter · Q3
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACERA SURGICAL via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · third_quarter · Q3
Issues related to Medicare reimbursement of nanofiber matrix technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); Build Back Better Act (H.R. 5376); and the Inflation Reduction Act (H.R. 5376).
Issues related to R&D tax credits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · third_quarter · Q3
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348).
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295) and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · second_quarter · Q2
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Senate and House Appropriations Committees report language on nuclear medicine event reporting.
ACERA SURGICAL via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · second_quarter · Q2
Issues related to Medicare reimbursement of nanofiber matrix technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · second_quarter · Q2
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); and the Build Back Better Act (H.R.5376).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · second_quarter · Q2
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209) and the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Issues related to lab analysis, review, coverage, and reimbursement of diagnostics and lab developed tests, including CMS coverage of T-cell immunity tests. This includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · second_quarter · Q2
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high-cost specialty drugs, pediatric mental health, other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus.
Issues related to Medicaid and other pediatric health issues. Issues related to hospital funding and the federal response to the COVID-19 virus. Issues related to Texas' Medicaid 1115 Waiver and Supplemental Payment and Directed Payment Programs.
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · first_quarter · Q1
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · first_quarter · Q1
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies appropriations issues. Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health and emergency department renovations.
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high-cost specialty drugs, pediatric mental health, other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus. Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136).
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · first_quarter · Q1
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues.
Issues related to lab analysis, review, coverage, and reimbursement of diagnostics and lab developed tests, including CMS coverage of T-cell immunity tests. This includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · first_quarter · Q1
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Senate and House Energy & Water Development Committee Appropriations report language on nuclear medicine event reporting.
ACERA SURGICAL via ARNOLD & PORTER KAYE SCHOLER LLP
2022 · first_quarter · Q1
Issues related to Medicare reimbursement of nanofiber matrix technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROOKDALE SENIOR LIVING, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · fourth_quarter · 4T
Reimbursement and regulatory issues related to assisted living and memory care. COVID-19 related issues, including the Provider Relief Fund established by the CARES Act (P.L. 116-136) and booster administration. Issues related to the Build Back Better Act (H.R. 5376).
Reimbursement and regulatory issues related to assisted living and memory care. COVID-19 related issues, including the Provider Relief Fund established by the CARES Act (P.L. 116-136) and booster administration. Issues related to the Build Back Better Act (H.R. 5376).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · fourth_quarter · Q4
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · fourth_quarter · Q4
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609). Senate and House Energy & Water Development Committee Appropriations report language on re-evaluation of nuclear medicine event reporting.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACERA SURGICAL via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · fourth_quarter · Q4
Issues related to Medicare reimbursement of nanofiber matrix technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · fourth_quarter · Q4
Issues related to lab analysis, review, coverage, and reimbursement of diagnostics and lab developed tests, including CMS coverage of T-cell immunity tests. This includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · fourth_quarter · Q4
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high-cost specialty drugs, pediatric mental health, other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus. Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Issues related to the Build Back Better Act (H.R. 5376).
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 4502). Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health.
CHILDREN'S HOSPITAL OF THE KING'S DAUGHTERS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Issues related to Medicaid and other pediatric health issues; policy issues related to hospitals and the federal response to the COVID-19 virus, including vaccine requirements, and ongoing COVID-19 response negotiations. Issues related to the Build Back Better Act (H.R. 5376).
Issues related to medical education, TRICARE, Medicaid/CHIP, children's mental health services, Defense Health Agency pediatric care, and other pediatric health issues; and policy issues related to hospitals and the federal response to the COVID-19 virus, including vaccine requirements, and ongoing COVID-19 response negotiations. Issues related to the Build Back Better Act (H.R. 5376).
BROOKDALE SENIOR LIVING, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Reimbursement and regulatory issues related to assisted living and memory care. COVID-19 related issues, including the Provider Relief Fund established by the CARES Act (P.L. 116-136) and booster administration. Issues related to the Build Back Better Act (H.R. 5376).
Reimbursement and regulatory issues related to assisted living and memory care. COVID-19 related issues, including the Provider Relief Fund established by the CARES Act (P.L. 116-136) and booster administration. Issues related to the Build Back Better Act (H.R. 5376).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
ACERA SURGICAL via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Issues related to Medicare reimbursement of nanofiber matrix technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROVENTION BIO, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Issues related to type 1 diabetes population screening and drug therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHATHOM PHARMACEUTICALS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Issues related to access to antibiotics.
Filing targets: HOUSE OF REPRESENTATIVES
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609). Senate Energy & Water Development Committee Appropriations report language on re-evaluation of nuclear medicine event reporting.
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 4479/S. 2609).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209).
Issues related to lab analysis, review, coverage, and reimbursement of diagnostics and lab developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · third_quarter · Q3
Issues related to Medicaid and other pediatric health issues. Issues related to hospital funding and the federal response to the COVID-19 virus. Issues related to Texas' Medicaid 1115 Waiver. Issues related to the Build Back Better Act (H.R. 5376).
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high-cost specialty drugs, other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus. Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Issues related to the Build Back Better Act (H.R. 5376).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. Medicare reimbursement of cardiac PET scans.
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. Medicare reimbursement of cardiac PET scans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, and the American Rescue Plan Act (H.R. 1319). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health.
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high cost specialty drugs, and other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus, including in the American Rescue Plan Act (H.R. 1319). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136).
PHATHOM PHARMACEUTICALS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Issues related to access to antibiotics.
Filing targets: HOUSE OF REPRESENTATIVES
ALVOGEN via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Issues related to domestic manufacturing of pharmaceuticals.
Filing targets: Health & Human Services, Dept of (HHS)
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Issues related to lab analysis, review, coverage, and reimbursement of diagnostics and lab developed tests.
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN COUNSELING ASSOCIATION via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Issues related to Medicare coverage of marriage and family therapist services and mental health counselor services. Issues related to mental health services during the public health emergency. Mental Health Access Improvement Act (H.R. 432/S. 828).
Issues related to Medicare coverage of marriage and family therapist services and mental health counselor services. Issues related to mental health services during the public health emergency. Mental Health Access Improvement Act (H.R. 432/S. 828).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROOKDALE SENIOR LIVING, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Reimbursement and regulatory issues related to assisted living and memory care; COVID-19 related issues.
Reimbursement and regulatory issues related to assisted living and memory care; COVID-19 related issues. Better Care Better Jobs Act (H.R. 4131/S. 2210).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHILDREN'S HOSPITAL OF THE KING'S DAUGHTERS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · second_quarter · Q2
Issues related to Medicaid and other pediatric health issues; policy issues related to hospitals and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations.
Issues related to medical education, TRICARE, Medicaid/CHIP, children's mental health services, Defense Health Agency pediatric care, and other pediatric health issues; and policy issues related to hospitals and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations.
The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, including pediatric mental health, and other pediatric health funding issues; and funding and policy issues related to health care and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations.
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. Medicare reimbursement of cardiac PET scans.
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. Medicare reimbursement of cardiac PET scans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to lab analysis and review of diagnostics and lab developed tests, including the American Rescue Plan Act (P.L. 117-2).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the American Rescue Plan Act (P.L. 117-2).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALVOGEN via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to domestic manufacturing of pharmaceuticals.
Filing targets: Health & Human Services, Dept of (HHS)
PHATHOM PHARMACEUTICALS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to access to antibiotics.
Filing targets: HOUSE OF REPRESENTATIVES
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high cost specialty drugs, and other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus, including in the American Rescue Plan Act (H.R. 1319). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136).
Issues related to Medicaid and other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus, including in the American Rescue Plan Act (H.R. 1319).
CHILDREN'S HOSPITAL OF THE KING'S DAUGHTERS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to medical education, TRICARE, Medicaid/CHIP, children's mental health services, Defense Health Agency pediatric care, and other pediatric health issues; policy issues related to hospitals and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations; and the American Rescue Plan Act (H.R. 1319).
Issues related to Medicaid and other pediatric health issues; policy issues related to hospitals and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations; and the American Rescue Plan Act (H.R. 1319).
BROOKDALE SENIOR LIVING, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to implementation of average sales price reporting requirements.
Issues related to patient access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLORADO REGIONAL HEALTH INFORMATION ORGANIZATION via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to health information exchanges and data modernization efforts, including support for health information exchanges during the COVID-19 response. Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260). American Rescue Plan Act of 2021 (P.L. 117-2).
Issues related to health information exchanges and data modernization efforts, including support for health information exchanges during the COVID-19 response. Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260). American Rescue Plan Act of 2021 (P.L. 117-2).
AMERICAN COUNSELING ASSOCIATION via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to Medicare coverage of marriage and family therapist services and mental health counselor services. Issues related to mental health services during the public health emergency. Mental Health Access Improvement Act (H.R. 945/S. 286). Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260). American Rescue Plan Act of 2021 (P.L. 117-2).
Issues related to Medicare coverage of marriage and family therapist services and mental health counselor services. Issues related to mental health services during the public health emergency. Mental Health Access Improvement Act (H.R. 945/S. 286). Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260). American Rescue Plan Act of 2021 (P.L. 117-2).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OPEN PHILANTHROPY ACTION FUND via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to rapid antigen COVID-19 testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. American Rescue Plan Act of 2021 (P.L. 117-2).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. American Rescue Plan Act of 2021 (P.L. 117-2).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVOGEN via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · RR
Issues related to domestic manufacturing of pharmaceuticals.
PHATHOM PHARMACEUTICALS via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · RR
Issues related to access to antibiotics.
BROOKDALE SENIOR LIVING, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · RR
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
OPEN PHILANTHROPY ACTION FUND via ARNOLD & PORTER KAYE SCHOLER LLP
2021 · first_quarter · RR
Issues related to federal support for rapid antigen testing.
NEBRASKA HEALTH INFORMATION INITIATIVE via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · 4T
Issues related to health information exchanges, data modernization efforts and prescription drug monitoring, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Issues related to health information exchanges, data modernization efforts and prescription drug monitoring, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
FERRING PHARMACEUTICALS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Issues related to reporting of average sales price to Medicare, including relevant provisions in Lower Drug Costs Now Act (H.R. 3), Prescription Drug Pricing Reduction Act (S. 2543), Prescription Drug STAR Act (H.R. 2113), Strengthening Average Sales Price Reporting Act (S. 2051), and Consolidated Appropriations Act, 2021 (H.R. 133).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Prescription Drug Pricing Reduction Act (S. 2543). Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHILDRENS HEALTH SYSTEM OF TEXAS via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), Disproportionate Share Hospital (DSH) Payments, surprise medical billing, medical education, high cost specialty drugs, and other pediatric health issues. Policy issues related to hospital funding and the federal response to the COVID-19 virus; including the Coronavirus and Relief Supplemental Appropriations Act, 2021 (H.R. 133) and HEROES Act (H.R. 6800). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136).
Federal funding support for childrens hospitals including CHGME, telehealth, and pediatric research, including the Consolidated Appropriations Act, 2021 (H.R. 133) and HEROES Act (H.R. 6800); Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development appropriations provisions. Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772). Medicare reimbursement of cardiac PET scans.
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772). Medicare reimbursement of cardiac PET scans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHILDREN'S HOSPITAL OF THE KING'S DAUGHTERS via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, including Children's Hospitals Graduate Medical Education (CHGME) program annual funding, pediatric mental health, and other pediatric health funding issues; funding and policy issues related to health care and the federal response to the COVID-19 virus (including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133) and HEROES Act (H.R. 6800)) and ongoing COVID-19 response negotiations.
Issues related to Disproportionate Share Hospital (DSH) payments, medical education, TRICARE, Medicaid/CHIP, children's mental health services, Defense Health Agency pediatric care, surprise medical billing, and other pediatric health issues; policy issues related to hospitals and the federal response to the COVID-19 virus (including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133) and HEROES Act (H.R. 6800)) and ongoing COVID-19 response negotiations.
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Issues related to lab analysis and review of diagnostics and lab developed tests, including VALID Act of 2020 (H.R. 6102/S. 3404), Eliminating Kickbacks in Recovery Act of 2018, and the 21st Century Cures 2.0 Concept Paper.
Issues related to lab analysis and review of diagnostics and lab developed tests, including the VALID Act of 2020 (H.R. 6102/S. 3404), Eliminating Kickbacks in Recovery Act of 2018, and 21st Century Cures 2.0 Concept Paper.
FY 2021 Commerce-Justice-Science Appropriations regarding the Eliminating Kickbacks in Recovery Act of 2018.
NEBRASKA HEALTH INFORMATION INITIATIVE via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Issues related to health information exchanges, data modernization efforts and prescription drug monitoring, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Issues related to health information exchanges, data modernization efforts and prescription drug monitoring, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
COLORADO REGIONAL HEALTH INFORMATION ORGANIZATION via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Issues related to health information exchanges and data modernization efforts, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Issues related to health information exchanges and data modernization efforts, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
AMERICAN COUNSELING ASSOCIATION via ARNOLD & PORTER KAYE SCHOLER LLP
2020 · fourth_quarter · Q4
Issues related to Medicare coverage of marriage and family therapist services and mental health counselor services. Issues related to mental health services during the public health emergency. Mental Health Access Improvement Act (H.R. 945/S. 286). Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Issues related to Medicare coverage of marriage and family therapist services and mental health counselor services. Issues related to mental health services during the public health emergency. Mental Health Access Improvement Act (H.R. 945/S. 286). Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Issues related to the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873 & H.R. 1946).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to Medicaid, CHIP, hospital funding, Texas' Medicaid 1115 Waiver, and other pediatric health issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Issues related to the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873 & H.R. 1946).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues and Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Fiscal Year 2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Act (H.R. 4502), and the Fiscal Year 2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 8295). Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health and emergency department renovations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Issues related to Medicaid and other pediatric health issues. Issues related to hospital funding and the federal response to the COVID-19 virus. Issues related to Texas' Medicaid 1115 Waiver and Supplemental Payment and Directed Payment Programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209). Also, research issues regarding cellular immunity - this includes H.R. 5745, the COVID-19 Access to Testing and Support for Immune Response Research Act of 2021.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to Medicaid and other pediatric health issues. Issues related to hospital funding and the federal response to the COVID-19 virus. Issues related to Texas' Medicaid 1115 Waiver and Supplemental Payment and Directed Payment Programs. Issues related to the Build Back Better Act (H.R. 5376).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FY 2022 Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 4502), including pediatric mental health, and other pediatric health funding issues; and funding and policy issues related to health care and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 4502). Issues related to the Provider Relief Fund established by the CARES Act (P.L. 116-136). Children's Health's Congressionally Directed Spending requests regarding pediatric mental health.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to Medicaid and other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus, including in the American Rescue Plan Act (H.R. 1319). Issues regarding Texas' Medicaid 1115 Waiver.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Federal funding support for childrens hospitals including Children's Hospital Graduate Medical Education (CHGME) program, telehealth, and pediatric research; including the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act and the American Rescue Plan Act (H.R. 1319). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, including pediatric mental health, and other pediatric health funding issues; the American Rescue Plan Act (H.R. 1319); and funding and policy issues related to health care and the federal response to the COVID-19 virus and ongoing COVID-19 response negotiations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to health information exchanges and data modernization efforts, including support for health information exchanges during the COVID-19 response. Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260). American Rescue Plan Act of 2021 (P.L. 117-2).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to health information exchanges, data modernization efforts and prescription drug monitoring, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to Medicaid Disproportionate Share Hospital (DSH) Payments, and other pediatric health issues. Policy issues related to hospital funding and the federal response to the COVID-19 virus; including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133) and HEROES Act (H.R. 6800).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
Issues related to Medicaid, Medicaid Disproportionate Share Hospital (DSH) payments, and other pediatric health issues; policy issues related to hospitals and the federal response to the COVID-19 virus (including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133) and HEROES Act (H.R. 6800)) and ongoing COVID-19 response negotiations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to health information exchanges, data modernization efforts and prescription drug monitoring, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to health information exchanges and data modernization efforts, including support for health information exchanges during the COVID-19 response. Continuing Appropriations Act, 2021 and Other Extensions Act (H.R. 8337). Funding and policy issues related to health care and federal response to the COVID-19 virus, including the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (H.R. 133).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE